ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Perspective Therapeutics, Inc. (CATX) stock declined over -4.35%, trading at $2.20 on AMEX, down from the previous close of $2.30. The stock opened at $2.33, fluctuating between $2.19 and $2.35 in the recent session.
Richland, WA 99354
United States
Website: https://www.perspectivetherapeutics.comContact: 509 375 1202Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Employees | 138 |
Beta | 1.26 |
Sales or Revenue | $10.80M |
5Y Sales Change% | -0.509% |
Fiscal Year Ends | June |
Sector | Healthcare |
Industry | Medical - Devices |